Inotek Pharmaceuticals has reported positive results for its INO-8875 glaucoma treatment.
The results of a Phase I/II randomised, double-blind, placebo-controlled clinical trial of INO-8875 showed that treatment was well tolerated and resulted in a statistically significant reduction in intraocular pressure (IOP).
Go deeper with GlobalData
The Phase I/II single ascending dose study, involved 84 subjects with primary open-angle glaucoma or ocular hypertension.
Inotek President and CEO Paul Howes said that INO-8875 is an important investigational agent that holds great potential for the treatment of glaucoma and other indications marked by elevated IOP.
“We intend to continue our Phase II programme with INO-8875 in glaucoma in 2010, while also continuing to advance our pipeline which includes novel therapeutic approaches to other serious ophthalmic diseases, including age-related macular degeneration and diabetic retinopathy,” Howes said.
The study was designed to evaluate the safety, tolerability and efficacy of INO-8875 administered topically to the eye.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
